Quantcast
Last updated on April 21, 2014 at 5:21 EDT

Latest Ipratropium Stories

2012-05-16 02:29:39

SAN DIEGO, May 16, 2012 /PRNewswire/ -- Elevation Pharmaceuticals, Inc., a pharmaceutical company focused on the development of new aerosol therapies for patients with respiratory diseases, announced today positive results from a Phase 2b study of EP-101 in patients with chronic obstructive pulmonary disease (COPD), a progressive disease comprising chronic bronchitis and emphysema caused largely by smoking. Patients with moderate to severe COPD treated with EP-101 after seven days had a...

2011-12-07 08:00:00

REDWOOD CITY, Calif., Dec. 7, 2011 /PRNewswire/ -- Pearl Therapeutics Inc. today announced positive top-line results from a randomized, double-blind, Phase 2b, dose-ranging study of glycopyrrolate, a long-acting muscarinic agonist (LAMA) delivered twice a day (BID) via metered-dose inhaler (GP MDI; PT001) in patients with moderate-to-severe COPD. Four doses of GP MDI were compared to placebo and Atrovent® HFA Inhalation Aerosol, a short-acting muscarinic...

2011-10-07 20:18:00

RIDGEFIELD, Conn., Oct. 7, 2011 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved COMBIVENT RESPIMAT, a new, propellant-free inhaler product that uses a slow-moving mist to deliver the same active ingredients of COMBIVENT Inhalation Aerosol in a metered dose inhaler (COMBIVENT MDI). COMBIVENT RESPIMAT will be available for patients in mid-2012. COMBIVENT RESPIMAT and COMBIVENT MDI are indicated for use...

2011-06-16 08:00:00

REDWOOD CITY, Calif., June 16, 2011 /PRNewswire/ -- Pearl Therapeutics Inc. today announced the advancement of its dual combination product candidate, PT003 and its individual components, PT001 and PT005 into a series of planned Phase 2 studies in patients with moderate-to-severe COPD. PT003 (GFF MDI) is an investigational inhaled combination bronchodilator product comprising glycopyrrolate (GP), a long-acting muscarinic antagonist (LAMA), and formoterol (FF), a well-known, established,...

2010-04-13 17:12:00

RIDGEFIELD, Conn., April 13 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that the U.S. Food and Drug Administration (FDA) has determined that the "essential use" status of Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol will be effective through December 31, 2013. With this ruling, COMBIVENT will remain on the market and available to the more than two million chronic obstructive pulmonary disease (COPD)...

2009-09-17 15:19:00

WASHINGTON, Sept. 17 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today advised consumers not to use certain respiratory medications purchased after Sept. 8, 2009 and manufactured by Dey L.P., a subsidiary of Mylan Inc., because the medications might have been part of a shipment being transported on a tractor-trailer stolen in Tampa, Fla., on Sept. 8, 2009. (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO) The respiratory medications, Ipratropium Bromide...

2009-09-17 16:01:54

Federal officials are warming consumers not to use certain respiratory medications purchased after Sept. 8, produced by Dey L.P., a subsidiary of Mylan Inc. The U.S. Food and Drug Administration said the medications might have been part of a shipment being transported on a tractor-trailer stolen in Tampa, Fla. The FDA said the respiratory medications -- Ipratropium Bromide Inhalation Solution, 0.02%, and Albuterol Sulfate Inhalation Solution, 0.083%, -- have not been recovered and might be...

2009-09-11 21:47:00

NAPA, Calif., Sept. 11 /PRNewswire-FirstCall/ -- Dey L.P., a subsidiary of Mylan Inc. (Nasdaq: MYL), today issued an advisory regarding the theft of two different types of its respiratory medications, Ipratropium Bromide Inhalation Solution, 0.02%, and Albuterol Sulfate Inhalation Solution, 0.083%, unit-dose vials. The lots were on a tractor-trailer that was stolen in the state of Florida. The NDC numbers for the Ipratropium product are 49502-685-31 (lot number F09089) and 49502-685-62...

2009-05-19 12:30:00

SAN DIEGO, May 19 /PRNewswire/ -- Data from two presentations highlighting the use of Perforomist(R) (formoterol fumarate) Inhalation Solution in moderate to severe chronic obstructive pulmonary disease (COPD) patients were featured today at the International Conference of the American Thoracic Society in San Diego. In one analysis, use of Perforomist Inhalation Solution, when added to maintenance tiotropium, resulted in improved pulmonary function, dyspnea (shortness of breath) and rescue...

2008-10-24 12:00:26

NAPA, Calif., Oct. 24 /PRNewswire-FirstCall/ -- Dey L.P., a subsidiary of Mylan Inc. , announced today the presentation of clinical data on Perforomist(TM) (formoterol fumarate) Inhalation Solution at the upcoming Annual International Scientific Assembly of the American College of Chest Physicians (CHEST), October 25 - 29 at the Pennsylvania Convention Center in Philadelphia. The data to be presented will include patient preference, dyspnea, and bronchodilation results for Perforomist(TM)...